{
    "clinical_study": {
        "@rank": "28315", 
        "acronym": "In_vitro_PAT", 
        "arm_group": {
            "arm_group_label": "healthy volunteers", 
            "description": "1 group with no treatment : They provide the blank plasma to be used at in vitro study."
        }, 
        "biospec_descr": {
            "textblock": "Plasma and white blood cells"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor and\n      its active metabolite (AR-C124910XX) and their effects on the pharmacodynamics of salicylic\n      acid. The study consist of two parts of in-vitro study as follows;\n\n        -  Part 1 : in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor\n           and its active metabolite.\n\n        -  Part 2 : in vitro study to evaluate the  pharmacodynamic interaction between ticagrelor\n           and its active metabolite and their effect on the pharmacodynamics of salicylic acid on\n           platelet  aggregation tests with the agonist of arachidonic acid."
        }, 
        "brief_title": "In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cardiovascular Diseases", 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "detailed_description": {
            "textblock": "This is a in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor and\n      its active metabolite (AR-C124910XX) and their effects on the pharmacodynamics of salicylic\n      acid. The study consist of two parts of in-vitro study as follows;\n\n        -  Part 1 : in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor\n           and its active metabolite. Platelet aggregation tests with the agonist of adenosine\n           diphosphate(ADP) will be assessed on the in-vitro mixtures of blank plasma and\n           randomized paired concentrations of ticagrelor + AR-C124910XX.\n\n        -  Part 2 : in vitro study to evaluate the  pharmacodynamic interaction between ticagrelor\n           and its active metabolite. Platelet aggregation tests with the agonist of arachidonic\n           acid will be assessed on the in-vitro mixtures of blank plasma plus randomized paired\n           concentrations of ticagrelor and AR-C124910XX and the invitro mixtures with blank\n           plasma and ticagrelor + AR-C124910XX + salicylic acid."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with body weight more than 50 kg and within 20% of the ideal body weight:\n             ideal body weight = (height[cm] - 100)*0.9.\n\n          -  Subjects who have received and understood completely the information regarding the\n             current study and given written informed consents to voluntarily participate in the\n             study and followed all instructions specified in the protocol.\n\n        Exclusion Criteria:\n\n          -  Subjects who have a history or presence of any clinically significant diseases.\n\n          -  Subjects who have any congenital or acquired haematological diseases.\n\n          -  Subjects who had whole blood donation within the last 2 months and component blood\n             donation within the last month.\n\n          -  Subject who took any concomitant medication including non-steroidal antiinflammatory\n             drugs(NASIDs) and vitamins currently or within 7 days prior to blood sampling."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "healthy volunteers"
            }
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777516", 
            "org_study_id": "AsanMC_CPT_PAT_2012", 
            "secondary_id": "A070001"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Salicylic Acid", 
                "Salicylates", 
                "Ticagrelor"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Platelet Aggregation", 
            "Cardiovascular Diseases", 
            "Salicylic Acid"
        ], 
        "lastchanged_date": "January 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "In Vitro Study to Evaluate the Pharmacodynamic Interaction Between Ticagrelor and Its Active Metabolite (AR-C124910XX) and Their Effects on the Pharmacodynamics of Salicylic Acid : Concentration-antiplatelet Effect Relationships", 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Hyeong-Seok Lim, M.D., PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Plasma which were collected from healthy volunteers were used to make mixtures of drugs, ticagrelor, AR-C124910XX and salicylic acid. ADP and arachidonic acid were used as the agonists of platelet aggregation.", 
            "measure": "Platelet aggregation(%) of the in vitro mixtures of blank plasma and drugs of the randomized paired concentrations", 
            "safety_issue": "No", 
            "time_frame": "The tolerability of volunteers after blood sampling will be followed for the duration of hospital stay, an expected average of 5 hours."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777516"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Hyeong-Seok Lim", 
            "investigator_title": "Associate Professor of the Department of Pharmacology and Therapeutics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Asan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Korea National Enterprise for Clinical Trials", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}